Mike Blue joined HistoSonics as President, CEO and Board Director in January 2017 and has over 25 years of leadership experience within the medical device sector, almost exclusively in interventional oncology. Since his start, HistoSonics has raised over $300M in equity financings resulting in significant value creation, successfully completed pivotal trials in multiple clinical indications, and is now commercializing the company’s breakthrough Edison Histotripsy Platform around the world. In August 2025, Mike also assumed the role of Chairman of the Board upon the closing of a majority investment valuing the company at $2.25B.

Prior to joining HistoSonics, Mike led the commercial organizations at NeuWave Medical, acquired by Johnson & Johnson in 2016, and superDimension, acquired by Covidien (MDT) in 2012. He started his career as an analyst at Anderson Consulting (Accenture).